Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Frontiers in Pharmacology
|
December 19, 2024
Deep brain stimulation combined with morroniside promotes neural plasticity and motor functional recovery after ischemic stroke
Yanxi Chen, Zhidong Xu, Yifu Ma, et al.
Cell Death & Disease
|
February 15, 2024
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8<sup>+</sup> T cells
Chenfeng Han, Minmin Ge, Pengfei Xing, et al.
BMJ Open
|
March 8, 2024
Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)
Yuehong Kong, Rongzheng Chen, Meiling Xu, et al.
Technology in Cancer Research & Treatment
|
July 25, 2024
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)
Yingying Xu, Yuehong Kong, Yifu Ma, et al.
Frontiers in Immunology
|
July 25, 2022
PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
Yuehong Kong, Xiangrong Zhao, Meiling Xu, et al.
Science Immunology
|
May 1, 2026
Citraconate preserves T cell stemness and antitumor immunity
Wenhui Li, Minmin Ge, Ziyi Luo, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Frontiers in Pharmacology
|
December 19, 2024
Deep brain stimulation combined with morroniside promotes neural plasticity and motor functional recovery after ischemic stroke
Yanxi Chen, Zhidong Xu, Yifu Ma, et al.
Cell Death & Disease
|
February 15, 2024
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8<sup>+</sup> T cells
Chenfeng Han, Minmin Ge, Pengfei Xing, et al.
BMJ Open
|
March 8, 2024
Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study)
Yuehong Kong, Rongzheng Chen, Meiling Xu, et al.
Technology in Cancer Research & Treatment
|
July 25, 2024
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)
Yingying Xu, Yuehong Kong, Yifu Ma, et al.
Frontiers in Immunology
|
July 25, 2022
PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
Yuehong Kong, Xiangrong Zhao, Meiling Xu, et al.
Science Immunology
|
May 1, 2026
Citraconate preserves T cell stemness and antitumor immunity
Wenhui Li, Minmin Ge, Ziyi Luo, et al.
Page
of 2